# Critical Evaluation: Computational De Novo Protein Binder Design for α-Synuclein Aggregation Inhibition
---
## Hypothesis 1: Structure-Based Targeting of the NACore β-Sheet Interface
### Specific Weaknesses
1. **Target validation assumption:** Cryo-EM structures (6H6B) represent mature fibril end-states, not the transient, low-population conformations that initiate aggregation. The "steric zipper" is only formed *after* nucleation; targeting this interface with a designed binder assumes structural continuity between fibril state and nucleation intermediate that has not been demonstrated.
2. **Oversimplified nucleation model:** The NACore is treated as the exclusive nucleation site. However, familial PD mutations are distributed throughout the protein (A30P in N-terminal repeat domain, E46K, H50Q, G53D, A53T in N-terminal/Central region). This suggests multiple surfaces contribute to early aggregation events. Mutating one interface does not prove it is the sole targetable nucleation driver.
3. **G73A mutation interpretation:** The cited G73A data shows reduced aggregation *kinetics*, but this does not establish that the mutation acts specifically at the β-strand interface. The mutation could alter local stability, monomer dynamics, or cofactor interactions—mechanisms unrelated to binder targeting.
4. **Assumes static pocket availability:** Structure-based docking presupposes a binding-competent pocket. The NACore in monomeric αS is highly dynamic; the β-strand conformation required for binder complementarity is not pre-formed but induced during aggregation. Designed binders may have negligible affinity for the monomeric state.
### Potential Counter-Evidence
- **Polymorphism:** αS forms multiple fibril polymorphs with distinct core architectures (e.g., Parkinson's vs. Multiple System Atrophy strains). This indicates the aggregation interface is not uniquely defined.
- **C-terminal truncation data:** C-terminal truncations markedly accelerate aggregation, demonstrating that sequences *outside* the NACore contribute to nucleation kinetics.
- **Primary vs. secondary nucleation:** A binder occupying the fibril-end interface does not address primary nucleation—the critical step generating new fibrils *de novo*. This distinction is absent from the hypothesis.
### Falsification Experiments
1. **Direct nucleation assay:** Use *in vitro* seeded growth kinetics (ThT fluorescence, AFM) with pre-formed fibril seeds at substoichiometric ratios. If the binder only blocks elongation (fibril-end capping) but not primary nucleation, seeds will still drive new fibril formation